
Globus Medical (GMED) Stock Forecast & Price Target
Globus Medical (GMED) Analyst Ratings
Bulls say
Globus Medical Inc is positioned for potential growth driven by faster-than-expected developments in the spine market and strong sales from its Enabling Technologies, with projections indicating a sequential improvement in sales. The company's robust performance in the U.S. spine sector and an impressive 10% growth in Nevro sales highlight its strong market presence and product demand. With anticipated improvements in organic growth, strong free cash flow, and the strategic benefits of ongoing integration efforts, the company is likely to achieve improved EBITDA margins and revenue growth, enhancing its overall financial outlook.
Bears say
Globus Medical faces several fundamental risks that contribute to a negative outlook on its stock, including slower-than-expected growth in the spine market and potential revenue disruptions due to the mergers of NuVasive and Nevro. The bear case scenario indicates a concerning trend of revenue growth slowing to low-single digits while margins are expected to remain flat, highlighting the potential for financial underperformance. Furthermore, significant challenges such as competitive dynamics, ineffective product launches, and delays in expanding into new musculoskeletal areas could adversely affect the company’s operational and financial metrics.
This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.
Globus Medical (GMED) Analyst Forecast & Price Prediction
Start investing in Globus Medical (GMED)
Order type
Buy in
Order amount
Est. shares
0 shares